Document:

CONSULTING AGREEMENT

 

This AGREEMENT is made
as of the 4th day of October, 2013, by and between Novelos Therapeutics, Inc., a Delaware corporation, with its principal executive
offices in Newton, Massachusetts and principal offices in Madison, Wisconsin (the “Company”), and Simon Pedder of Fort
Mill, South Carolina (the “Consultant”).

 

WITNESSETH

 

WHEREAS, the Company
and the Consultant desire to set forth the terms and conditions on which, from and after the Effective Date, (i) the Consultant
shall render services to the Company, and (ii) the Company shall compensate the Consultant for such services;

 

NOW THEREFORE, in consideration
of the mutual covenants contained herein, the Company and the Consultant (individually a “Party” and together the “Parties”)
agree as follows:

 

1. Term. This
Agreement shall be effective on October 4, 2013 (the “Effective Date”) and end at the close of business on March 31,
2014. This Agreement may be terminated or extended at any time with the mutual consent of both parties. Either party may terminate
this Agreement for any reason; provided, however, that the terminating party shall first provide written notice to the other party
at least 15 days prior to the effective date of termination.

 

2. Consulting Services.
The Consultant shall serve the Company as Acting Chief Executive Officer. In addition, concurrently with the Effective Date, the
Consultant has been elected as a Director of the Company. In such positions, the Consultant shall have the duties, responsibilities
and authorities as determined and designated from time to time by the board of directors, including, without limitation, management
authority with respect to, and responsibility for, the overall day-to-day business and affairs of the Company (the “Consulting
Services”). The Consultant shall serve under the direction and supervision of, and report to, the board of directors. Notwithstanding
the above, the Consultant shall not be required to perform any duties and responsibilities which would result in noncompliance
with or violation of any applicable law or regulation.

 

3. Independent Contractor.
In furnishing the Consulting Services, the Consultant understands that he will at all times be acting as an independent contractor
of the Company and, as such, will not be an employee of the Company and will not by reason of this Agreement or by reason of his
Consulting Services to the Company be entitled to participate in or to receive any benefit or right under any of the Company’s
employee benefit or welfare plans. The Consultant also will be responsible for paying all withholding and other taxes required
by law to be paid as and when the same become due and payable.

 

4. Compensation.
The compensation payable to the Consultant under this Agreement shall be as follows:

 

4.1. Consulting
Fee. The Company shall pay the Consultant a consulting fee of $30,000 per month, payable in periodic installments in accordance
with the Company’s usual practice, but no less frequently than monthly. Said consulting fee shall be inclusive of any Director’s
fee to which the Consultant would otherwise be entitled and shall be prorated for actual days of service in any month in which
this Agreement is terminated.

 

    	 

    	 

    

 

4.2. Equity Awards.
The Company shall grant to the Consultant the following equity awards:

 

(a)An option
to purchase up to 3,360,000 shares of the Common Stock, representing approximately five percent (5%) of the outstanding stock and
stock options of the Company (the “5% Option”). The exercise price per share shall be equal to the closing market price
on the date of grant. The option shall vest in four equal annual installments beginning on the first anniversary of the date of
grant. The option shall be evidenced by an option agreement in substantially the form attached hereto as Exhibit A and Schedule
I thereto (the “5% Option Agreement”); and

 

(b)An option
to purchase up to 1,925,573 shares of the Common Stock, which option is intended to provide protection against dilution of the
5% Option (the “Anti-Dilution Option”) due to the issuance of shares of the Common Stock following the exercise of
certain outstanding warrants to purchase the Common Stock. The exercise price per share shall be equal to the greater of $0.75
and the closing market price on the date of grant. The option shall be evidenced by an option agreement in substantially the form
attached hereto as Exhibit A and Schedule II thereto (the “Anti-Dilution Option Agreement”).

 

4.3. Business Expenses.
The Company shall reimburse the Consultant for all reasonable travel and other business expenses incurred by the Consultant in
the performance of his duties and responsibilities, including transportation (both local and from home to office) and in connection
with the Consultant’s general availability to work from the Company’s offices in Madison, Wisconsin, subject to such
reasonable requirements with respect to substantiation and documentation as may be specified by the Company.

 

5. Service.

 

5.1. Extent of Service.
The Consultant shall, subject to the direction and supervision of the board of directors, devote a mutually satisfactory amount
of his time, his best efforts and business judgment, his skill and knowledge to the advancement of the Company’s interests
and to the discharge of his duties and responsibilities hereunder; provided, however, that nothing herein shall be construed
as preventing the Consultant from:

 

(a) investing
his assets in such form or manner as shall not require any material services on his part in the operations or affairs of the companies
or the other entities in which such investments are made;

 

(b) serving
on the board of directors of or as a consultant to any other company, provided that he obtains the prior approval of a majority
of the board of directors to serve on more than one other board to render any material services with respect to the operations
or affairs of any such company; or

 

(c) engaging
in religious, charitable or other community or non-profit activities which do not impair his ability to fulfill his duties and
responsibilities under this Agreement.

 

    	- 2 -

    	 

    

 

6. Confidential Information.
The Consultant understands that the Company continually obtains and develops valuable proprietary and confidential information
concerning its technical and business affairs (the “Confidential Information”) which may become known to the Consultant
in connection with the performance of the Consulting Services.

 

6.1. The Consultant
acknowledges that all Confidential Information, whether or not in writing and whether or not labeled or identified as confidential
or proprietary, is and shall remain the exclusive property of the Company or the third party providing such information to the
Consultant or the Company. By way of illustration, but not limitation, Confidential Information may include inventions, trade secrets,
technical information, know-how, research and development activities of the Company, product and marketing plans, customer and
supplier information and information disclosed to the Company or to the Consultant by third parties of a proprietary or confidential
nature or under an obligation of confidence. Confidential Information is contained in various media, including patent applications,
research data and observations, computer programs in object and/or source code, technical specifications, notebooks, supplier and
customer lists, internal financial data and other documents and records of the Company. Confidential Information also shall include
all documents, records and other tangible items of any kind in which Confidential Information is stored, maintained or recorded
or from which Confidential Information may be readily ascertained or derived (whether in the form of documents, correspondence,
memoranda, books, records, files, notes, plans, reports, programs, drawings, sketches, designs, graphics, photographs, prints,
mats, films, negatives, recordings, magnetic media, software (whether in source code or object code), disks, diskettes, CD, CD-ROM,
electronic files or other media, charts, manuals, materials or any other medium. Such Confidential Information shall include all
such information not generally known by the trade or public, even though such information has been disclosed to one or more third
parties pursuant to publishing agreements, development agreements, distribution agreements, joint research agreements, confidentiality
agreements, disclosure agreements or other agreements or collaborations entered into by any of the Company. The definition of Confidential
Information applies equally to information acquired, learned, or disclosed prior to, simultaneously with, or after the date of
this Agreement.

 

6.2. The Consultant
agrees that the Consultant shall not, during the term of the Consultant’s engagement by the Company and thereafter, publish,
disclose or otherwise make available to any third party any Confidential Information except as expressly authorized herein or in
writing by the Company. The Consultant may disclose Confidential Information to (i) directors, employees, consultants and
representatives of the Company, to (ii) accountants, financial advisors and legal counsel of the Consultant, who have a bona
fide need to know such information and who are bound by an obligation not to use or disclose such information without authorization
from the Company and to (iii) other parties that enter into confidentiality or non-disclosure agreements with the Company
and to whom such Confidential Information will be disclosed for legitimate business purposes of the Company. The Consultant agrees
that the Consultant shall use such Confidential Information only in the performance of the Consultant’s duties for the Company
and in accordance with any Company policies with respect to the protection of Confidential Information. The Consultant agrees not
to use such Confidential Information for the Consultant’s own benefit or for the benefit of any other person or business
entity.

 

    	- 3 -

    	 

    

 

6.3. The Consultant
agrees to exercise all reasonable precautions to protect the integrity and confidentiality of Confidential Information in the Consultant’s
possession and not to remove any materials containing Confidential Information from the Company’s premises except to the
extent necessary to the Consultant’s performance of services for the benefit of the Company. Upon the termination of the
Consultant’s engagement with the Company, or at any time upon the Company’s request, the Consultant shall return immediately
to the Company any and all materials containing any Confidential Information then in the Consultant’s possession or under
the Consultant’s control.

 

6.4. Confidential Information
shall not include information which (i) is or becomes generally known within the Company’s industry or otherwise through
no fault of the Consultant; (ii) was known to the Consultant at the time it was disclosed as evidenced by the Consultant’s
written records in existence at the time of disclosure; (iii) is lawfully and in good faith made available to the Consultant
by a third party who did not derive it from the Company and who imposes no obligation of confidence on the Consultant; or (iv) is
required to be disclosed by a governmental authority or by order of a court of competent jurisdiction, provided that the Consultant
shall cooperate with the Company at its expense in seeking to obtain all applicable governmental or judicial protection available
for like material and provide reasonable advance notice to the Company.

 

7. Non-Competition.
As long as the Consultant is retained by the Company and for a period of six (6) months after termination of this Agreement, the
Consultant shall not, directly or indirectly, alone or as a partner, officer, director, employee, consultant, agent, or independent
contractor of any company or business organization, (a) engage in any business activity which is directly or indirectly in
competition with the business of the Company in the area of the development of drugs for the treatment or diagnosis of cancer based
on cancer-targeting technologies (“Competitive Activity”) or (b) solicit or contact in connection with,
or in furtherance of, a Competitive Activity any of the Company’s employees, consultants, agents, suppliers, customers, or
prospects that were such with respect to the Company at any time during the one year immediately preceding the date of termination
or that become such with respect to the Company at any time during the three (3) months immediately following the date of termination.
The provisions of this Section 7 shall survive the termination of this Agreement. The Consultant represents and warrants that the
covenant imposed by this Section 7 would not cause him an undue hardship.

 

8. Specific Performance.
The Consultant agrees that any breach of Sections 6 or 7 of this Agreement by the Consultant could cause irreparable damage and
that in the event of such breach the Company shall have, in addition to any and all remedies available at law or in equity, the
right to an injunction, specific performance or other equitable relief to prevent the violation of the Consultant’s obligations
hereunder.

 

    	- 4 -

    	 

    

 

9. Section 409A of the Code.

 

9.1. It is intended
that this Agreement comply with or be exempt from Section 409A of the Code and the Treasury Regulations and IRS guidance thereunder
(collectively referred to as “Section 409A”). Notwithstanding anything to the contrary in this Agreement, this Agreement
shall, to the maximum extent possible, be administered, interpreted, and construed in a manner consistent with Section 409A (it
being understood that the Company shall in no event have any obligation to indemnify the Consultant in respect of any taxes incurred
under Section 409A). To the extent that any reimbursement, fringe benefit, or other, similar plan or arrangement in which the Consultant
participates during the term of this Agreement or thereafter provides for a “deferral of compensation” within the meaning
of Section 409A, (a) the amount of expenses eligible for reimbursement provided to the Consultant during any calendar year shall
not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to the Consultant in any other calendar
year, (b) the reimbursements for expenses for which the Consultant is entitled to be reimbursed shall be made on or before the
last day of the calendar year following the calendar year in which the applicable expense is incurred, (c) the right to payment
or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit, and (d) the reimbursements
shall be made pursuant to objectively determinable and nondiscretionary Company policies and procedures regarding such reimbursement
of expenses. If and to the extent required to comply with Section 409A, no payment or benefit required to be paid under this Agreement
on account of termination of the Consultant’s engagement shall be made unless and until the Consultant incurs a “separation
from service” within the meaning of Section 409A. In the case of any amounts payable to the Consultant under this Agreement
that may be treated as payable in the form of “a series of installment payments”, as defined in Treasury Regulation
Section 1.409A-2(b)(2)(iii), the Consultant’s right to receive such payments shall be treated as a right to receive a series
of separate payments for purposes of such Treasury Regulation. If any paragraph of this Agreement provides for payment within a
time period, the determination of when such payment shall be made within such time period shall be solely in the discretion of
the Companies.

 

9.2. If the Consultant
is a “specified employee” as determined pursuant to Section 409A as of the date of the Consultant’s termination
of engagement and if any payment provided for in this Agreement or otherwise both (x) constitutes a “deferral of compensation”
within the meaning of Section 409A and (y) cannot be paid or provided in the manner otherwise provided without subjecting the Consultant
to additional tax, interest, or penalties under Section 409A, then any such payment shall be delayed until the earlier of (i) the
date which is 6 months after the Consultant’s “separation from service” within the meaning of Section 409A for
any reason other than death, or (ii) the date of the Consultant’s death. The provisions of this paragraph shall only
apply if, and to the extent, required to avoid the imputation of any tax, penalty, or interest pursuant to Section 409A. Any payment
or benefit otherwise payable or to be provided to the Consultant upon or in the 6 month period following the Consultant’s
“separation from service” that is not so paid or provided by reason of this Section 9 shall be accumulated and paid
or provided to the Consultant in a single lump sum, as soon as practicable (and in all events within 15 days) after the date that
is 6 months after the Consultant’s “separation from service” (or, if earlier, as soon as practicable, and in
all events within 15 days, after the date the Consultant’s death).

 

    	- 5 -

    	 

    

 

10. Miscellaneous.

 

10.1. Conflicting Agreements.
The Consultant hereby represents and warrants that the execution of this Agreement and the performance of his obligations hereunder
shall not breach or be in conflict with any other agreement to which he is a party or is bound, and that he is not now subject
to any covenants against competition or similar covenants which would affect the performance of his obligations hereunder.

 

10.2. Definition of “Person”.
For purposes of this Agreement, the term “Person” shall mean an individual, a corporation, an association, a partnership,
an estate, a trust and any other entity or organization.

 

10.3. Withholding.
All payments made by the Company under this Agreement shall be net of any tax or other amounts required to be withheld by the Company
under applicable law.

 

10.4. Arbitration.

 

(a) Except
for claims of fraud or intentional misrepresentation, which shall be filed in any state or federal court having jurisdiction over
the parties, any claim regarding the Consultant’s ongoing relationship with the Company that is not resolved by mutual agreement
shall be resolved solely and exclusively by binding arbitration to be conducted in Chicago, Illinois before a single arbitrator
(the “Arbitrator”) and shall be conducted in accordance with the American Arbitration Association Rules and Procedures
unless specifically modified herein.

 

(b) The parties
covenant and agree that the arbitration shall commence within 90 days of the date on which a written demand for arbitration is
filed by any party hereto. In connection with the arbitration proceeding, the Arbitrator shall have the power to order the production
of documents by each party and any third-party witnesses. In addition, each party may take up to six depositions as of right, and
the Arbitrator may in his or her discretion allow additional depositions upon good cause shown by the moving party. There shall
be no interrogatories or requirements for or response to requests for admission but the parties may require production of documents.
In connection with any arbitration, each party shall provide to the other, no later than seven (7) business days before the date
of the arbitration, the identity of all persons that may testify at the arbitration and a copy of all documents that may be introduced
at the arbitration or considered or used by a party’s witnesses or experts. The Arbitrator’s decision and award shall
be made and delivered within six (6) months of the selection of the Arbitrator. The Arbitrator’s decision shall set forth
a reasoned basis for any award of damages or finding of liability. The Arbitrator shall not have power to award damages in excess
of actual compensatory damages and shall not multiply actual damages or award punitive damages or any other damages that are specifically
excluded under this Agreement, and each party hereby irrevocably waives any claim to such damages in connection with any such arbitration.

 

(c) The parties
covenant and agree that they will participate in the arbitration in good faith and that they will (i) bear their own attorneys’
fees, costs and expenses in connection with the arbitration, and (ii) share equally in the fees and expenses charged by the
Arbitrator. Any party unsuccessfully refusing to comply with an order of the Arbitrator shall be liable for costs and expenses,
including reasonable attorneys’ fees, incurred by the other party in enforcing the award. In the case of temporary or preliminary
injunctive relief any party may proceed in court prior to, during or after arbitration for the purpose of avoiding immediate and
irreparable harm or to enforce its rights under any non-disclosure, confidentiality or non-competition covenants; provided, that
the right to equitable relief by a court is not intended to derogate from this arbitration procedure.

 

    	- 6 -

    	 

    

 

10.5. Assignment; Successors and Assigns, etc.
Neither the Company nor the Consultant may make any assignment of this Agreement or any interest herein, by operation of law or
otherwise, without the prior written consent of the other party and without such consent any attempted transfer or assignment shall
be null and of no effect; provided, however, that the Company may assign its rights under this Agreement without the consent
of the Consultant in the event either Company shall hereafter effect a reorganization, consolidate with or merge into any other
Person, or transfer all or substantially all of its properties or assets to any other Person. This Agreement shall inure to the
benefit of and be binding upon the Company and the Consultant, and their respective successors, executors, administrators, heirs
and permitted assigns. In the event of the Consultant’s death prior to the completion by the Company of all payments due
his under this Agreement, the Company shall continue such payments to the Consultant’s beneficiary designated in writing
to the Company prior to his death (or to his estate, if he fails to make such designation).

 

10.6. Enforceability.
If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent
jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than
those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of
this Agreement shall be valid and enforceable to the fullest extent permitted by law.

 

10.7. Waiver.
No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any
party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this
Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

 

10.8. Notices.
Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered
in person or sent by registered or certified mail, postage prepaid, to the Consultant at the last address the Consultant has filed
in writing with the Company or, in the case of the Company, at its main office, attention of the board of directors.

 

10.9. Amendment.
This Agreement may be amended or modified only by a written instrument signed by the Consultant and by a duly authorized representative
of the Company.

 

10.10. Counterparts; Facsimile Signatures.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument, and in pleading or proving any provision of this Agreement it shall not be necessary
to produce more than one such counterpart. A signature sent by telecopy or facsimile transmission shall be as valid and binding
upon a Party as an original signature of such Party.

 

    	- 7 -

    	 

    

 

10.11. Governing Law.
This contract and shall be construed under and be governed in all respects by the laws of the State of Delaware without regard
to its conflict of laws principles.

 

* * * * *

 

IN WITNESS WHEREOF,
this Agreement has been executed by the Company, by its duly authorized officer, and by the Consultant, as of the date first above
written.

 

	 	NOVELOS THERAPEUTICS, INC.
	 	 
	 	By: /s/ Stephen Hill
	 	Name: Stephen Hill
	 	Title: Chairman of the Board of Directors
	 	 
	 	CONSULTANT:
	 	 
	 	/s/ Simon Pedder
	 	Simon Pedder

 

    	- 8 -

    	 

    

Exhibit
A

 

Non-Qualified Stock Option

 

Date of Grant:
_____________, 2013

 

NON-QUALIFIED STOCK OPTIONS

 

Granted by

 

NOVELOS THERAPEUTICS, INC.

(together with its subsidiaries, the “Company”)

 

to

 

Simon Pedder

(the “Holder”)

 

For valuable consideration,
the receipt of which is hereby acknowledged, and pursuant to that certain Consulting Agreement by and between the Holder and the
Company (the “Consulting Agreement”), the Company hereby grants to the Holder the following options:

 

Section 1. Grant
of Options. Subject to the terms and conditions hereinafter set forth, the Holder is hereby given the rights and options to
purchase from the Company shares of the Company’s common stock, $.00001 par value per share (the “Common Stock”).
Schedule I and Schedule II attached hereto and hereby incorporated herein set forth, with respect to these options, (i) their
expiration dates (on which dates the options shall terminate in all respects, and all rights and options to purchase shares hereunder
shall terminate), (ii) their exercise prices per share, (iii) the maximum number of shares that the Holder may purchase
upon exercise thereof, and (iv) their vesting schedules. They also set forth applicable conditions that the Company incorporates
herein. The right to purchase shares hereunder shall be cumulative.

 

Section 2. Exercise
of Option. Each option hereunder may be exercised only to the extent such option has vested pursuant to the terms of Section
1. Purchase of any shares hereunder shall be made by delivery to the Company of a written notice of exercise specifying the number
of shares with respect to which the option is to be exercised and the address to which the certificate representing such shares
is to be mailed, accompanied by either (a) cash, certified or bank check or postal money order payable to the order of the
Company for an amount equal to the option price of such shares, (b) if authorized by the Company’s Board of Directors
(the “Board”), shares of Common Stock of the Company having a fair market value equal to or less than the option price
of such shares accompanied by cash or a certified or bank check or postal money order in an amount equal to the difference, if
any, between the option price of such shares and the fair market value of such shares, (c) if authorized by the Board, by
reducing the number of shares of Common Stock otherwise issuable to the Holder upon exercise of the Option by a number of shares
of Common Stock having a fair market value equal to aggregate option price , or (d) if authorized by the Board, any combination
of the foregoing. For the purpose of the preceding sentence, the fair market value of the shares of Common Stock so delivered to
the Company shall be determined in accordance with procedures adopted by the Board or, if appointed, a committee of the Board authorized
to administer Company options (the “Committee”).

 

    	- 9 -

    	 

    

 

Section 3. Conditions
and Limitations. The Holder agrees for a period of 90 days from the effective date of underwritten public offerings of Common
Stock of the Company under the Securities Act of 1933, as amended (the “Securities Act”), upon request of the underwriters
managing any underwritten offering of the Company’s securities, not to sell, make any short sale of, loan, grant any option
for the purchase of, or otherwise dispose of any shares issued pursuant to the exercise of this option, without the prior written
consent of the Company and such underwriters.

 

Section 4. Delivery
of Shares. Within a reasonable time following the receipt by the Company of the written notice and payment of the option price
for the shares to be purchased thereunder, the Company will deliver or cause to be delivered to the Holder (or if any other individual
or individuals are exercising this option, to such individual or individuals) at the address specified pursuant to Section 2 hereof
a certificate or certificates for the number of shares with respect to which the option is then being exercised, registered in
the name of the Holder (or the name or names of the individual or individuals exercising the option, either alone or jointly with
another person or persons with rights of survivorship, as the individual or individuals exercising the option shall prescribe in
writing to the Company); provided, however, that such delivery shall be deemed effected for all purposes when a stock transfer
agent shall have deposited such certificate or certificates in the United States mail, addressed to the Holder (or such individual
or individuals) at the address so specified; and provided further that if any law, regulation or order of the Commission or other
body having jurisdiction in the premises shall require the Company or the Holder (or the individual or individuals exercising this
option) to take any action in connection with the sale of the shares then being purchased, then, subject to the other provisions
of this paragraph, the date on which such sale shall be deemed to have occurred and the date for the delivery of the certificates
for such shares shall be extended for the period necessary to take and complete such action, it being understood that the Company
shall have no obligation to take and complete any such action.

 

Section 5. Adjustments
Upon Changes in Capitalization. The existence of this option shall not affect in any way the right or power of the Company
or its stockholders to make or authorize any or all adjustments, recapitalizations, reorganizations or other changes in the Company’s
capital structure or its business, or any merger or consolidation of the Company, or any issue of bonds, debentures, preferred
or prior preference stock ahead of or affecting the Common Stock or the rights thereof, or the dissolution or liquidation of the
Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether
of a similar character or otherwise.

 

    	- 10 -

    	 

    

 

If the Company shall
effect a subdivision or consolidation of shares or other capital readjustment, the payment of a stock dividend, or other increase
or reduction of the number of shares of the Common Stock outstanding, without receiving compensation therefor in money, services
or property, then the number, class, and per share price of shares of stock subject to this option shall be appropriately adjusted
in such a manner as to entitle the Holder to receive upon exercise of this option, for the same aggregate cash consideration, the
same total number and class of shares that the owner of an equal number of outstanding shares of Common Stock would own as a result
of the event requiring the adjustment.

 

Except as hereinbefore
expressly provided, the issue by the Company of shares of stock of any class, or securities convertible into shares of stock of
any class, for cash or property, or for labor or services, either upon direct sale or upon the exercise of rights or warrants to
subscribe therefor, or upon conversion of shares or obligations of the Company convertible into such shares or other securities,
shall not affect, and no adjustment by reason thereof shall be made with respect to, the number or price of shares of Common Stock
then subject to this option.

 

Section 6. Effect
of Certain Transactions. If the Company is a party to a merger or reorganization with one or more other corporations, whether
or not the Company is the surviving or resulting corporation, or if the Company consolidates with or into one or more other corporations,
or if the Company is liquidated or sells or otherwise disposes of substantially all its assets to another corporation (each hereinafter
referred to as a “Transaction”), in any case while this option remains outstanding, the Board may take one or more
of the following actions: (a) provide that after the effective date of such Transaction this option shall remain outstanding
and shall be exercisable in shares of Common Stock or, if applicable, shares of such stock or other securities, cash or property
as the holders of shares of Common Stock received pursuant to the terms of such Transaction; (b) may accelerate the time for
exercise of this option, so that from and after a date prior to the effective date of such Transaction this option shall be exercisable
in full; (c) may cancel unexercised options as of the effective date of such Transaction, provided that notice of such cancellation
shall be given to the Holder and the Holder shall have the right to exercise this option during a specified period preceding the
effective date of such transaction; (d) make or provide for a cash payment to the Holder equal to the difference between (i) the
fair market value of the per share consideration (whether cash, securities or other property or any combination of the above) the
holder of a share of Common Stock will receive upon consummation of the Transaction (the “Per Share Transaction Price”)
times the number of shares of Common Stock subject to the vested portion of the Option (to the extent then exercisable at prices
not equal to or in excess of the Per Share Transaction Price) and (ii) the aggregate exercise price of such shares, in exchange
for the termination of the Option. To the extent that this Option is exercisable at a price equal to or in excess of the Per Share
Transaction Price, the Board may provide that the Option shall terminate immediately upon the consummation of the Transaction without
any payment being made to the Holder. 

 

Section 7. Rights
of Holder. No person shall, by virtue of the granting of this option to the Holder, be deemed to be a holder of any shares
purchasable under this option or to be entitled to the rights or privileges of a holder of such shares unless and until this option
has been exercised with respect to such shares and they have been issued pursuant to that exercise of this option.

  

The granting of this
option shall not impose upon the Company any obligations to employ or to continue to employ the Holder or, if applicable, to continue
the Holder as a director of the Company; and the right of the Company to terminate the employment of the Holder shall not be diminished
or affected by reason of the fact that this option has been granted to the Holder.

 

    	- 11 -

    	 

    

 

Nothing herein contained
shall impose any obligation upon the Holder to exercise this option.

 

At all times while
any portion of this option is outstanding, the Company shall: (i) reserve and keep available, out of shares of its authorized
and unissued stock or reacquired shares, a sufficient number of shares of its Common Stock to satisfy the requirements of this
option; (ii) comply with the terms of this option promptly upon exercise of the option rights; and (iii) pay all fees
or expenses necessarily incurred by the Company in connection with the issuance and delivery of shares pursuant to the exercise
of this option.

 

Section 8. Tax Withholding.
The Company’s obligation to deliver shares upon exercise of this Option shall be subject to the Holder’s satisfaction
of any federal, state and local income and employment tax withholding requirements.

 

Section 9. Transfer
and Termination. This option is not transferable by the Holder otherwise than by will or the laws of descent and distribution,
unless approved by the Company in writing.

 

In the event the Holder
ceases to provide consulting services to the Company, except in circumstances where the Holder continues to provide services as
an employee of the Company, the Holder’s right to exercise any unexercised portion of either Option shall cease immediately
and each Option shall terminate.

 

In the event that after
entering into an employment agreement with the Company, the Holder’s employment is terminated for any reason by the Company
other than for Cause or by the Holder for Good Reason, then each Option shall terminate upon the one year anniversary of the Holder’s
termination of employment. Until such anniversary the Holder shall have the right to exercise that portion of either Option that
was vested as of the date of the Holder’s termination of employment, provided, the Holder has delivered any Release contemplated
by Holder’s employment agreement.

 

In the event the Holder's
employment is terminated by the Company for Cause (as defined below), the Holder's right to exercise any unexercised portion of
each Option shall cease immediately as of the date of termination, and each Option shall thereupon terminate. Notwithstanding anything
herein to the contrary, if subsequent to the Holder's termination of employment, but prior to the exercise of either Option, the
Board of Directors of the Company determines that, either prior or subsequent to the Holder's termination, the Holder engaged in
conduct which would constitute Cause, then the Holder shall immediately cease to have any right to exercise either Option and each
Option shall thereupon terminate.

 

In the event the Holder’s
employment is terminated by Holder other than for Good Reason, the Holder shall have the right to exercise that portion of either
Option that was vested at the date of termination of employment for a period of 90 days after such date of termination of employment
and each Option shall thereupon terminate.

 

Section 10. Definitions
for Purposes of this Option Agreement. For purposes of this agreement:

 

    	- 12 -

    	 

    

 

(a) The term “Cause”
shall mean: (i) Holder’s dishonesty relating to the Company or its assets (including, without limitation, theft or embezzlement
of Company funds or assets); (ii) a material misstatement or misrepresentation by Holder to the Company with respect to his educational
and professional background and experience; (iii) Holder’s commission of any action with the intent to injure the Company,
its business or its assets; (iv) Holder is indicted for any felony, or for any misdemeanor which may interfere with the performance
of his duties or responsibilities to the Company; (v) Holder violates any material directive, policy, standard or instruction of
the Board with respect to the operation of the Company’s business; (vi) Holder fails to obey any direction of the Board which
is not illegal; (vii) Holder’s willful noncompliance in any material respect with any laws or regulations, foreign or domestic,
in the operation of the Company’s business; (viii) Holder’s material breach of any of his obligations pursuant to any
written agreement with the Company or any fiduciary duty arising under law; (ix) Holder’s gross negligence or willful misconduct
with respect to the business affairs of the Company or with respect to performing his duties or responsibilities under any written
agreement with the Company (other than on account of a medically determinable disability which renders the Holder incapable of
performing such services); or (x) Holder’s unlawful use of alcohol or controlled substances or other drugs.

 

(b) The term “Good
Reason” shall mean: (i) the failure of the board of directors to elect the Holder to the offices of President and Chief Executive
Officer, or to continue the Holder in such offices; (ii) the failure by the stockholders of the Company to continue to elect the
Holder to the board of directors; (iii) the failure by the Company to pay compensation as provided for in Holder’s employment
agreement, except for across the board cuts applicable to all officers of the Company on an equal percentage basis; provided that
such reduction is approved by the board of directors; (iv) any reduction of Holder’s base salary or material reduction in
other benefits or any material change by the Company to the Holder’s function, duties, authority, or responsibilities, which
change would cause the Holder’s position with the Company to become one of lesser responsibility, importance, or scope from
the position and attributes thereof in effect; and (v) a material breach by the Company of any of the other provisions of Holder’s
employment agreement.

 

(c) The term “Change
of Control” shall mean: (i) the sale of all or substantially all of the assets or issued and outstanding capital stock of
the Company; (ii) merger or consolidation involving the Company in which stockholders of the Company immediately before such merger
or consolidation do not own immediately after such merger or consolidation capital stock or other equity interests of the surviving
corporation or entity representing more than fifty percent (50%) in voting power of capital stock or other equity interests of
such surviving corporation or entity outstanding immediately after such merger or consolidation; or (iii) a change, without the
approval of the board of directors, in the composition of the board of directors such that directors who were serving as of the
date of the Holder’s employment began cease to constitute a majority of the board of directors.

 

Section 11. Notice.
Any notice to be given to the Company hereunder shall be deemed sufficient if addressed to the Company and delivered to the office
of the Company, One Gateway Center, Suite 504, Newton, MA 02458, attention of the Chairman of the Board of Directors, or such other
address as the Company may hereafter designate.

 

    	- 13 -

    	 

    

 

Any notice to be given
to the Holder hereunder shall be deemed sufficient if addressed to and delivered in person to the Holder at his address furnished
to the Company or when deposited in the mail, postage prepaid, addressed to the Holder at such address.

 

Section 12. Governing Law. This option
shall be governed by and construed in accordance with the laws of the State of Delaware.

 

Section 13. Date
of Grant. This option shall be effective on the Date of Grant set forth on page 1 hereof.

 

IN WITNESS WHEREOF,
the parties have executed this option, or caused this option to be executed, as of the Date of Grant.

 

	 	 	Novelos Therapeutics, Inc.
	 	 	 
	 	 	By:	 
	 	 	 
	Acknowledged and accepted:	 	 
	 	 	 
	 	 	 
	Holder	 	 

 

    	- 14 -

    	 

    

 

SCHEDULE I - 5% Option

 

NOVELOS THERAPEUTICS, INC.

 

Non-Qualified Stock Option

 

	1.	 	Name of Holder:	 	Simon Pedder
	 	 	 	 	 
	2.	 	Date of Grant:	 	_____________, 2013
	 	 	 	 	 
	3.	 	Maximum Number of shares for	 	 
	 	 	which this Option is exercisable:	 	3,360,000
	 	 	 	 	 
	4.	 	Exercise (purchase) price per share:	 	$______ (the closing market price on the Date of Grant).
	 	 	 	 	 
	5.	 	Expiration Date of Option:	 	_____________, 2023 (unless terminated earlier pursuant to Section 9 of the Option).
	 	 	 	 	 
	6.	 	Vesting Schedule:	 	 

 

This Option shall become exercisable
in four equal annual installments of 840,000 shares per year beginning on the first anniversary of the Date of Grant, provided
that the Holder is engaged or employed by the Company on each such anniversary. All vesting shall cease upon the date of termination
of the Holder’s engagement or employment with the Company for any reason, provided, however, that in the event that
after his entering into an employment agreement with the Company, the Holder’s employment is terminated either (i) by the
Company for any reason other than for Cause (as defined in the Option) or (ii) by the Holder for Good Reason (as defined in the
Option), any installment of this Option that would have vested during the one year period following such termination if the Holder
had remained employed shall vest upon the date of the termination of the Holder’s employment. This Option shall terminate
immediately upon termination of the Holder’s employment by the Company for Cause.

 

In the event that within twelve
(12) months of a Change in Control (as defined in the Option), either (i) the Company terminates the Holder’s employment
other than for Cause or (ii) the Holder terminates his own employment for Good Reason then (A) if the Option remained
outstanding following such Change in Control, one hundred percent of the unvested portion of the Option shall vest immediately;
or (B) to the extent that any unvested portion of the Option was terminated at the time of the Change in Control without any
payment to the Holder, a cash payment shall be made to the Holder, upon the date of such termination, equal to the difference between
(x) the Per Share Transaction Price times the number of shares of Common Stock subject to such unvested Portion of the Option
and (y) the aggregate exercise price of such unvested shares.

  

		7.	All shares purchased upon exercise of this Option are subject to the lockup agreement set forth
in Section 3 of the Option, and to the other terms of the Option.

 

	Acknowledged and accepted:	 
	 	 
	 	 
	Holder	 

 

    	- 15 -

    	 

    

 

SCHEDULE II - Anti-Dilution Option

 

NOVELOS THERAPEUTICS, INC.

 

Non-Qualified Stock Option

 

	1.	 	Name of Holder:	 	Simon Pedder
	 	 	 	 	 
	2.	 	Date of Grant:	 	_____________, 2013
	 	 	 	 	 
	3.	 	Maximum Number of shares for	 	 
	 	 	which this Option is exercisable:	 	1,925,573
	 	 	 	 	 
	4.	 	Exercise (purchase) price per share:	 	The greater of $0.75 and ($______) the closing market price on the Date of Grant.
	 	 	 	 	 
	5.	 	Expiration Date of Option:	 	_____________, 20__ (unless terminated earlier pursuant to Section 9 of the Option).
	 	 	 	 	 
	6.	 	Vesting Schedule:	 	 

 

(a) This Option shall become
exercisable upon the issuance of shares of Common Stock following the exercise of warrants to purchase Common Stock, issued by
the Company prior to March 1, 2013 and representing an aggregate of 36,585,895 shares of Common Stock (each, a “Warrant”);
provided that the Holder is employed by the Company at the time of such issuance. One share shall become exercisable for each 19
shares issued upon exercise of a Warrant.

 

(b) In the event that Common
Stock is issued upon the exercise of any Warrant during the period in which the Holder is providing services to the Company pursuant
to the Consulting Agreement between the Holder and the Company dated October 4, 2013, and prior to the date on which the Holder
becomes an employee of the Company, the Option shall vest as described in subsection (a) above as if the Holder were an employee
of the Company at the time of such issuance, but the Holder shall not be entitled to exercise such vested portion of the Option
unless and until the Holder becomes an employee of the Company. Such vested portion of the Option shall become exercisable as of
the date on which the Holder’s employment with the Company commences.

 

(c) All vesting shall cease upon
the date of termination of the Holder’s employment for any reason.

 

		7.	All shares purchased upon exercise of this Option are subject to the lockup agreement set forth
in Section 3 of the Option, and to the other terms of the Option.

  

	Acknowledged and accepted:	 
	 	 
	 	 
	Holder	 

 

    	- 17 -EMPLOYMENT AGREEMENT

 

This AGREEMENT is made
as of the 4th day of October, 2013, by and between Novelos Therapeutics, Inc., a Delaware corporation, with its principal executive
offices in Newton, Massachusetts and principal offices in Madison, Wisconsin (the “Company”), and Simon Pedder of Fort
Mill, South Carolina (the “Executive”).

 

WITNESSETH

 

WHEREAS, the Company
and the Executive desire to set forth the terms and conditions on which, from and after the Effective Date, (i) the Company
shall employ the Executive, (ii) the Executive shall render services to the Company, and (iii) the Company shall compensate
the Executive for such services;

 

NOW THEREFORE, in consideration
of the mutual covenants contained herein, the Company and the Executive (individually a “Party” and together the “Parties”)
agree as follows:

 

1. Employment.

 

1.1. Term of Employment.
This Agreement shall be effective on April 1, 2014 or such other date as the Company and the Executive shall mutually agree in
writing (the “Effective Date”), and employment hereunder shall be at will. Notwithstanding the foregoing, the term
of employment (the “Term”) shall end on the date on which the Executive’s employment is terminated by either
Party in accordance with the provisions herein.

 

1.2. Title and Responsibilities.
The Executive shall serve the Company as President and Chief Executive Officer. In addition, the Executive has been elected as
a Director of the Company. In such positions, the Executive shall have the duties, responsibilities and authorities as determined
and designated from time to time by the board of directors, including, without limitation, management authority with respect to,
and responsibility for, the overall day-to-day business and affairs of the Company. The Executive shall serve under the direction
and supervision of, and report to, the board of directors. Notwithstanding the above, the Executive shall not be required to perform
any duties and responsibilities which would result in noncompliance with or violation of any applicable law or regulation.

 

2. Compensation and Benefits.
The compensation and benefits payable to the Executive under this Agreement shall be as follows:

 

2.1. Salary.
For all services rendered by the Executive to the Company, the Executive shall be entitled to receive a base salary at the rate
of $350,000 per year beginning on the Effective Date. The Executive’s base salary shall be reviewed annually by the compensation
committee of the board of directors, with the first review no later than the first anniversary of the Effective Date, and shall
be subject to increase from time to time as approved by the compensation committee of the board of directors. In addition, if the
compensation committee of the board of directors increases the Executive’s annual base salary, such increased annual base
salary shall become a floor below which such annual base salary shall not fall without the Executive’s written consent. Executive’s
salary shall be payable in periodic installments in accordance with the Company’s usual practice for its senior executives,
but no less frequently than monthly.

 

    	 

    	 

    

 

2.2. Temporary Accommodation.
For the first six (6) months of employment, the Company shall reimburse the Executive for reasonable costs of lodging, meals, transportation
(both local and from home to office) and other similar expenses (such costs and expenses not to exceed $4,000 per month) in connection
with the Executive’s general availability to work from the Company’s offices in Madison, Wisconsin.

 

2.3. Bonus.
The Executive shall be eligible to receive an annual bonus at the discretion of the compensation committee of the board of directors
based on the Executive’s performance, which shall not exceed fifty percent (50%) of the Executive’s base salary.

 

2.4. Equity Awards. In connection
with the execution and delivery of a Consulting Agreement dated October 4th, 2013, the Company has granted to the Executive (i)
an option to purchase up to 3,360,000 shares of the Common Stock, representing approximately five percent (5%) of the outstanding
stock and stock options of the Company (the “5% Option”) and (ii) an option to purchase up to 1,925,573 shares of the
Common Stock, which option is intended to provide protection against dilution of the 5% Option (the “Anti-Dilution Option”)
pursuant to an option agreement (the “Option Agreement”). The Employment Agreement constitutes the continuation of
the provision of services of the Executive contemplated by Section 9 of the Option Agreement.

 

The Executive shall
be eligible to receive periodic future stock option grants at the discretion of the board of directors.

 

2.5. Regular Benefits.
The Executive shall also be entitled to participate in any and all employee benefit plans, medical insurance plans, disability
income plans, retirement plans, bonus incentive plans, and other benefit plans from time to time in effect for senior executives
of the Company. Such participation shall be subject to (i) the terms of the applicable plan documents, (ii) generally
applicable policies of the Company and (iii) the discretion of the board of directors or any administrative or other committee
provided for in or contemplated by such plan.

 

2.6. Business Expenses.
The Company shall reimburse the Executive for all reasonable travel and other business expenses incurred by the Executive in the
performance of his duties and responsibilities, subject to such reasonable requirements with respect to substantiation and documentation
as may be specified by the Company. In no event shall any reimbursement be made later than the last day of the year following the
year in which the expenses were incurred.

 

2.7. Vacation.
The Executive shall be entitled to five (5) weeks of paid vacation per year, to be taken at such times and intervals as shall be
determined by the Executive consistent with his responsibilities.

 

    	- 2 -

    	 

    

 

3. Service.

 

3.1. Extent of Service.
The Executive shall, subject to the direction and supervision of the board of directors, devote his full time, best efforts and
business judgment, skill and knowledge to the advancement of the Company’s interests and to the discharge of his duties and
responsibilities hereunder; provided, however, that nothing herein shall be construed as preventing the Executive from:

 

(a) investing
his assets in such form or manner as shall not require any material services on his part in the operations or affairs of the companies
or the other entities in which such investments are made;

 

(b) serving
on the board of directors of any other company, provided that he obtains the prior approval of a majority of the board of
directors to serve on more than one other board and shall not be required to render any material services with respect to the operations
or affairs of any such company; or

 

(c) engaging
in religious, charitable or other community or non-profit activities which do not impair his ability to fulfill his duties and
responsibilities under this Agreement.

 

4. Termination by the Company.

 

4.1. Termination by Company for Cause.
The Executive’s employment hereunder may be terminated by the Company, without further liability on the part of the Company,
effective immediately, by the board of directors for Cause (as such term is defined in Section 4.2) by written notice to the Executive
setting forth in reasonable detail the nature of such Cause.

 

4.2. Definition of Cause.
For purposes of this agreement, “Cause” shall mean:

 

(a) Executive’s
dishonesty relating to the Company or its assets (including, without limitation, theft or embezzlement of Company funds or assets);

 

(b) A material
misstatement or misrepresentation by Executive to the Company with respect to his educational and professional background and experience;

 

(c) Executive’s
commission of any action with the intent to injure the Company, its business or its assets;

 

(d) Executive
is indicted for any felony, or for any misdemeanor which may interfere with the performance of his duties or responsibilities under
this Agreement;

 

(e) Executive
violates any material directive, policy, standard or instruction of the Board with respect to the operation of the Company’s
business;

 

(f) Executive
fails to obey any direction of the Board which is not illegal;

 

(g) Executive’s
willful noncompliance in any material respect with any laws or regulations, foreign or domestic, in the operation of the Company’s
business;

 

(h) Executive’s
material breach of any of his obligations pursuant to this Agreement or any fiduciary duty arising under law;

 

    	- 3 -

    	 

    

 

(i) Executive’s
gross negligence or willful misconduct with respect to the business affairs of the Company or with respect to performing his duties
or responsibilities under this agreement (other than on account of a medically determinable disability which renders the
Executive incapable of performing such services); or

 

(j) Executive’s
unlawful use of alcohol or controlled substances or other drugs.

 

4.3. Termination Procedure.
With respect to the circumstances described in clauses (e) through (i) of Section 4.2, a termination by reason of any such circumstances
shall be deemed to be for Cause only if such circumstances are not cured by the Executive in all material respects within 30 days
following written notice thereof to the Executive, which notice shall identify in reasonable detail the facts that lead the Company
to believe that such circumstances exist and shall give Executive an opportunity to response; provided, however, that Executive
shall be entitled to only one notice and one cure period with respect to each alleged breach. In each case, in determining Cause,
the alleged acts or omissions of the Executive shall be measured against standards prevailing in the industry generally and the
ultimate existence of Cause must be confirmed by a majority of the board of directors (excluding the Executive) at a meeting prior
to any termination therefor. In the event of such a confirmation, the Company shall notify the Executive that the Company intends
to terminate the Executive’s employment for Cause under this Section 4 (the “Confirmation Notice”).

 

4.4. Termination of Obligations.
In the event of termination pursuant to Section 4.1, all obligations of the Company under this Agreement, other than the Company’s
obligations under the provisions of COBRA, shall terminate as of the date specified in the Confirmation Notice, but vested rights
of the parties hereunder as of such date shall not be affected.

 

4.5. Termination by the Company Without Cause.
The Executive’s employment with the Company may be terminated without cause by a majority of the board of directors on five
(5) business days prior written notice to the Executive (or, in lieu of such notice, the Executive’s base salary for one
week), provided, however, that the Company shall have the obligation upon any such termination to make the payments to the
Executive provided for under Section 6 of this Agreement.

 

5. Termination by the Executive

 

5.1. Termination by the Executive for Good Reason.
The Executive shall be entitled to terminate his employment hereunder for Good Reason (as defined in Section 5.3), provided
that (i) within 30 days of the first occurrence of one or more of the events listed in Section 5.3 below the Executive
delivers to the board of directors written notice of his intention to terminate employment for Good Reason, which notice specifies
in reasonable detail the circumstances claimed to give rise to such right, (ii) the Company shall have 30 days after receipt of
such notice to cure such circumstances, and (iii) failing a cure, the Executive terminates employment within 10 days after the
expiration of the 30 day period set forth in clause (ii).

 

Upon any such termination, the Executive
shall be entitled to receive the benefits set forth in Section 6.

 

    	- 4 -

    	 

    

 

5.2. Other Voluntary Termination by the Executive.
The Executive may effect, upon thirty (30) days prior written notice to the Company, which notice may be waived by the Company,
a Voluntary Termination of his employment hereunder. A “Voluntary Termination” shall mean a termination of employment
by the Executive on his own initiative other than a termination for Good Reason. If the Executive’s employment is
so terminated due to Voluntary Termination, the Executive shall be entitled to his base salary up to the date of termination. Provision
of medical benefits shall be in accordance with the provisions of COBRA.

 

5.3. Good Reason.
For purposes of this Agreement, the term “Good Reason” shall mean any of the following:

 

(a) the failure
of the board of directors to elect the Executive to the offices of President and Chief Executive Officer, or to continue the Executive
in such offices;

 

(b) the failure
by the stockholders of the Company to continue to elect the Executive to the board of directors;

 

(c) the failure
by the Company to pay compensation as provided for in Sections 2.1, 2.2, 2.4, 2.5
or 2.6, except for across the board cuts applicable to all officers of the Company on an equal percentage basis; provided
that such reduction is approved by the board of directors;

 

(d) there
occurs any reduction of base salary or material reduction in other benefits or any material change by the Company to the Executive’s
function, duties, authority, or responsibilities in effect on the date hereof or as set forth in this Agreement, which change would
cause the Executive’s position with the Company to become one of lesser responsibility, importance, or scope from the position
and attributes thereof in effect on the date hereof or as set forth in this Agreement (and any such material change shall be deemed
a continuing breach of this Agreement); and

 

(e) a material
breach by the Company of any of the other provisions of this Agreement.

 

5.4. Change of Control.
For purposes of this Agreement, the term “Change of Control” means (i) the sale of all or substantially all of
the assets or issued and outstanding capital stock of the Company, (ii) merger or consolidation involving the Company in which
stockholders of the Company immediately before such merger or consolidation do not own immediately after such merger or consolidation
capital stock or other equity interests of the surviving corporation or entity representing more than fifty percent (50%) in voting
power of capital stock or other equity interests of such surviving corporation or entity outstanding immediately after such merger
or consolidation, or (iii) a change, without the approval of the board of directors, in the composition of the board of directors
such that directors who were serving as of the date of this Agreement cease to constitute a majority of the board of directors.

 

    	- 5 -

    	 

    

 

6. Certain Termination Benefits.
In the event of termination pursuant to Section 4.5 or Section 5.1, the Executive shall be entitled to certain benefits (the “Termination
Benefits”), subject to the following provisions:

 

6.1. Benefits.
The Termination Benefits are:

 

(a) Payment of Salary.
For a period of six (6) months following the date of the Executive’s termination, the Executive shall continue to receive
the installments of base salary set forth in Section 2.1 payable when and as if the Executive had continued to be employed by the
Company.

 

(b) Option Acceleration and Exercise.
Contingent upon the Executive’s execution and delivery of the release discussed below, in the event of a termination pursuant
to Sections 4.5 or 5.1, the 5% Option shall be vested as to such number of additional shares of Common Stock as if the Executive
had been employed for a period ending on the first anniversary of termination. In the event of such termination within twelve (12)
months of Change of Control, one hundred percent (100%) of the Executive’s unvested 5% Option shall vest. In either instance
the 5% Option shall remain exercisable for a period ending on the first anniversary of termination.

 

(c) Benefit Continuation.
For the six (6) month period subsequent to the date of termination, provided that the Executive has elected COBRA coverage, the
Company shall pay the portion of the Executive’s medical insurance COBRA premium equal to the medical insurance premium paid
by the Company for the Executive prior to the date of termination, provided however that the Company in its sole discretion may
elect to make a lump sum cash payment equal to the aggregate of such premiums in lieu of paying the premiums.

 

6.2. Release and Procedure.
The Company’s obligation to make payments pursuant to this Section 6 shall be conditioned upon the Executive’s execution
of a release in favor of the Company and its affiliates in the form attached hereto as Exhibit A (which the Company agrees to execute
and deliver simultaneously), subject to the following provisions.

 

(a)         The
Company will deliver the release to the Executive for execution no later than eight days after the Executive’s termination
of employment.

 

(b)         The
Executive must execute and deliver the release within 21 days after receipt thereof.

 

(c)         If
the Executive has revocation rights, he shall exercise such rights, if at all, not later than seven days after executing the release.

 

Subject to the execution and effectiveness
of such release, any payments that, pursuant to this Section 6, would otherwise be payable within the 46 day period commencing
on termination of employment shall be paid in a lump sum within 10 days after execution of the release; provided that, if the 46
day period begins in one calendar year and ends in the subsequent calendar year, the payment shall be made in the subsequent calendar
year.

 

(d)         The
failure of the Executive to provide the release within the time periods specified above will relieve the Company of its obligations
to make the payments and accelerate the options covered in Section 6.1.

 

    	- 6 -

    	 

    

 

7. Death, Disability.
The Executive’s employment shall terminate immediately upon the death or Disability of the Executive. “Disability”
means Executive’s failure by reason of sickness, accident or physical or mental disability to substantially perform the duties
and responsibilities of his employment with the Company for a period of ninety (90) consecutive days. In the event of termination
under this Section 7, the Executive or his estate shall receive the Executive’s Pre-Termination Compensation as defined in
Section 6.1, and fifty percent (50%) of the Executive’s unvested options shall vest and all vested options held by the Executive
shall remain exercisable for a period ending of the first anniversary of termination.

 

8. Applicability of Section 280G of the Code.

 

8.1. Limitation of Benefit.
In the event that any payment or benefit arising out of or in connection with a change of ownership or effective control of the
Company or a substantial portion of its assets within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended
(the “Code”, and such change, a “280G Change in Control”), that is made or provided, or to be made or provided,
by the Company (or any successors thereto or affiliates thereof) to the Executive, whether pursuant to the terms of this Agreement
or any other plan, agreement, or arrangement (any such payment or benefit, a “Parachute Payment”) would be subject
to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Parachute Payments shall be reduced
to the extent necessary to eliminate the imposition of the Excise Tax.

 

8.2. Determination.
A determination as to whether any reduction in the Executive’s Parachute Payments is required and if so, as to the amount
of reduction so required, shall be made by no later than 30 days after the closing of the transaction or the occurrence of the
event that constitutes the 280G Change in Control, or as soon thereafter as administratively practicable. Such determination, and
the assumptions to be utilized in arriving at such determination, shall be made reasonably and in good faith by the Company.

 

8.3. Order of Reductions.
Any reduction in the Parachute Payments required to be made shall be made first with respect to Parachute Payments payable in cash
before being made in respect of any Parachute Payments to be provided in the form of benefits or equity award acceleration, and
in the form of benefits before being made with respect to equity award acceleration, and in any case, shall be made with respect
to such Parachute Payments in inverse order of the scheduled dates or times for the payment or provision of such Parachute Payments.

 

8.4. Scope.
For the avoidance of doubt, the provisions of this Section 8 are intended to apply to any and all payments or benefits available
to the Executive under this Agreement or any other plan, agreement, or arrangement of the Company under which the Executive may
receive Parachute Payments, and shall supersede any contrary language in such plan, agreement, or arrangement.

 

9. Confidential Information.
Executive understands that the Company continually obtains and develops valuable proprietary and confidential information concerning
its technical and business affairs (the “Confidential Information”) which may become known to Executive in connection
with Executive’s employment by the Company.

 

    	- 7 -

    	 

    

 

9.1. Executive acknowledges
that all Confidential Information, whether or not in writing and whether or not labeled or identified as confidential or proprietary,
is and shall remain the exclusive property of the Company or the third party providing such information to Executive or the Company.
By way of illustration, but not limitation, Confidential Information may include inventions, trade secrets, technical information,
know-how, research and development activities of the Company, product and marketing plans, customer and supplier information and
information disclosed to the Company or to Executive by third parties of a proprietary or confidential nature or under an obligation
of confidence. Confidential Information is contained in various media, including patent applications, research data and observations,
computer programs in object and/or source code, technical specifications, notebooks, supplier and customer lists, internal financial
data and other documents and records of the Company. Confidential Information also shall include all documents, records and other
tangible items of any kind in which Confidential Information is stored, maintained or recorded or from which Confidential Information
may be readily ascertained or derived (whether in the form of documents, correspondence, memoranda, books, records, files, notes,
plans, reports, programs, drawings, sketches, designs, graphics, photographs, prints, mats, films, negatives, recordings, magnetic
media, software (whether in source code or object code), disks, diskettes, CD, CD-ROM, electronic files or other media, charts,
manuals, materials or any other medium. Such Confidential Information shall include all such information not generally known by
the trade or public, even though such information has been disclosed to one or more third parties pursuant to publishing agreements,
development agreements, distribution agreements, joint research agreements, confidentiality agreements, disclosure agreements or
other agreements or collaborations entered into by any of the Company. The definition of Confidential Information applies equally
to information acquired, learned, or disclosed prior to, simultaneously with, or after the date of this Agreement.

 

9.2. Executive agrees
that Executive shall not, during the term of Executive’s engagement by the Company and thereafter, publish, disclose or otherwise
make available to any third party any Confidential Information except as expressly authorized herein or in writing by the Company.
Executive may disclose Confidential Information to (i) directors, employees, consultants and representatives of the Company,
to (ii) accountants, financial advisors and legal counsel of Executive, who have a bona fide need to know such information
and who are bound by an obligation not to use or disclose such information without authorization from the Company and to (iii) other
parties that enter into confidentiality or non-disclosure agreements with the Company and to whom such Confidential Information
will be disclosed for legitimate business purposes of the Company. Executive agrees that Executive shall use such Confidential
Information only in the performance of Executive’s duties for the Company and in accordance with any Company policies with
respect to the protection of Confidential Information. Executive agrees not to use such Confidential Information for Executive’s
own benefit or for the benefit of any other person or business entity.

 

9.3. Executive agrees
to exercise all reasonable precautions to protect the integrity and confidentiality of Confidential Information in Executive’s
possession and not to remove any materials containing Confidential Information from the Company’s premises except to the
extent necessary to Executive’s employment for the benefit of the Company. Upon the termination of Executive’s employment
by the Company, or at any time upon the Company’s request, Executive shall return immediately to the Company any and all
materials containing any Confidential Information then in Executive’s possession or under Executive’s control.

 

    	- 8 -

    	 

    

 

9.4. Confidential Information
shall not include information which (i) is or becomes generally known within the Company’s industry or otherwise through
no fault of Executive; (ii) was known to Executive at the time it was disclosed as evidenced by Executive’s written
records in existence at the time of disclosure; (iii) is lawfully and in good faith made available to Executive by a third
party who did not derive it from the Company and who imposes no obligation of confidence on Executive; or (iv) is required
to be disclosed by a governmental authority or by order of a court of competent jurisdiction, provided that Executive shall cooperate
with the Company at its expense in seeking to obtain all applicable governmental or judicial protection available for like material
and provide reasonable advance notice to the Company.

 

10. Non-Competition.
In the event of termination, the Executive shall not, for a period of six (6) months after termination, directly or indirectly,
alone or as a partner, officer, director, employee, consultant, agent, or independent contractor of any company or business organization,
(a) engage in any business activity which is directly or indirectly in competition with the business of the Company in the
area of the development of drugs for the treatment or diagnosis of cancer based on cancer-targeting technologies (“Competitive
Activity”) or (b) solicit or contact in connection with, or in furtherance of, a Competitive Activity any of
the Company’s employees, consultants, agents, suppliers, customers, or prospects that were such with respect to the Company
at any time during the one year immediately preceding the date of termination or that become such with respect to the Company at
any time during the three (3) months immediately following the date of termination; provided, however, that at the election
of the Company, the obligations under this Section 10 shall survive for a period of one (1) year from the termination of employment
on condition that the Company provide the Termination Benefits set forth in Section 6.1(a) and (c) for the duration of such period.
The provisions of this Section 10 shall survive the termination of this Agreement. The Executive represents and warrants that the
covenant imposed by this Section 10 would not cause him an undue hardship.

 

11. No Mitigation; No Offset.
In the event of any termination of employment under this Agreement, the Executive shall be under no obligation to seek other employment
or to mitigate damages, and there shall be no offset against any amounts due to the Executive under this Agreement for any reason,
including, without limitation, on account of any remuneration attributable to any subsequent employment that the Executive may
obtain. Any amounts due under this Agreement are in the nature of severance payments or liquidated damages, or both, and are not
in the nature of a penalty.

 

12. Specific Performance.
The Executive agrees that any breach of Sections 9 or 10 of this Agreement by the Executive could cause irreparable damage and
that in the event of such breach the Company shall have, in addition to any and all remedies available at law or in equity, the
right to an injunction, specific performance or other equitable relief to prevent the violation of the Executive’s obligations
hereunder.

 

    	- 9 -

    	 

    

 

13. Section 409A of the Code.

 

13.1. It is intended
that this Agreement comply with or be exempt from Section 409A of the Code and the Treasury Regulations and IRS guidance thereunder
(collectively referred to as “Section 409A”). Notwithstanding anything to the contrary in this Agreement, this Agreement
shall, to the maximum extent possible, be administered, interpreted, and construed in a manner consistent with Section 409A (it
being understood that the Company shall in no event have any obligation to indemnify the Executive in respect of any taxes incurred
under Section 409A). To the extent that any reimbursement, fringe benefit, or other, similar plan or arrangement in which the Executive
participates during the Term or thereafter provides for a “deferral of compensation” within the meaning of Section
409A, (a) the amount of expenses eligible for reimbursement provided to the Executive during any calendar year shall not affect
the amount of expenses eligible for reimbursement or in-kind benefits provided to the Executive in any other calendar year, (b)
the reimbursements for expenses for which the Executive is entitled to be reimbursed shall be made on or before the last day of
the calendar year following the calendar year in which the applicable expense is incurred, (c) the right to payment or reimbursement
or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit, and (d) the reimbursements shall be made
pursuant to objectively determinable and nondiscretionary Company policies and procedures regarding such reimbursement of expenses.
If and to the extent required to comply with Section 409A, no payment or benefit required to be paid under this Agreement on account
of termination of the Executive’s employment shall be made unless and until the Executive incurs a “separation from
service” within the meaning of Section 409A. In the case of any amounts payable to the Executive under this Agreement that
may be treated as payable in the form of “a series of installment payments”, as defined in Treasury Regulation Section
1.409A-2(b)(2)(iii), the Executive’s right to receive such payments shall be treated as a right to receive a series of separate
payments for purposes of such Treasury Regulation. If any paragraph of this Agreement provides for payment within a time period,
the determination of when such payment shall be made within such time period shall be solely in the discretion of the Companies.

 

13.2. If the Executive
is a “specified employee” as determined pursuant to Section 409A as of the date of the Executive’s termination
of employment and if any payment or benefit provided for in this Agreement or otherwise both (x) constitutes a “deferral
of compensation” within the meaning of Section 409A and (y) cannot be paid or provided in the manner otherwise provided without
subjecting the Executive to additional tax, interest, or penalties under Section 409A, then any such payment or benefit shall be
delayed until the earlier of (i) the date which is 6 months after the Executive’s “separation from service”
within the meaning of Section 409A for any reason other than death, or (ii) the date of the Executive’s death. The provisions
of this paragraph shall only apply if, and to the extent, required to avoid the imputation of any tax, penalty, or interest pursuant
to Section 409A. Any payment or benefit otherwise payable or to be provided to the Executive upon or in the 6 month period following
the Executive’s “separation from service” that is not so paid or provided by reason of this Section 13 shall
be accumulated and paid or provided to the Executive in a single lump sum, as soon as practicable (and in all events within 15
days) after the date that is 6 months after the Executive’s “separation from service” (or, if earlier, as soon
as practicable, and in all events within 15 days, after the date the Executive’s death).

 

14. Miscellaneous.

 

14.1. Conflicting Agreements.
The Executive hereby represents and warrants that the execution of this Agreement and the performance of his obligations hereunder
shall not breach or be in conflict with any other agreement to which he is a party or is bound, and that he is not now subject
to any covenants against competition or similar covenants which would affect the performance of his obligations hereunder.

 

    	- 10 -

    	 

    

 

14.2. Definition of “Person”.
For purposes of this Agreement, the term “Person” shall mean an individual, a corporation, an association, a partnership,
an estate, a trust and any other entity or organization.

 

14.3. Withholding.
All payments made by the Company under this Agreement shall be net of any tax or other amounts required to be withheld by the Company
under applicable law.

 

14.4. Arbitration.

 

(a) Except
for claims of fraud or intentional misrepresentation, which shall be filed in any state or federal court having jurisdiction over
the parties, any claim regarding the Executive’s ongoing relationship with the Company that is not resolved by mutual agreement
shall be resolved solely and exclusively by binding arbitration to be conducted in Chicago, Illinois before a single arbitrator
(the “Arbitrator”) and shall be conducted in accordance with the American Arbitration Association Rules and Procedures
unless specifically modified herein.

 

(b) The parties
covenant and agree that the arbitration shall commence within 90 days of the date on which a written demand for arbitration is
filed by any party hereto. In connection with the arbitration proceeding, the Arbitrator shall have the power to order the production
of documents by each party and any third-party witnesses. In addition, each party may take up to six depositions as of right, and
the Arbitrator may in his or her discretion allow additional depositions upon good cause shown by the moving party. There shall
be no interrogatories or requirements for or response to requests for admission but the parties may require production of documents.
In connection with any arbitration, each party shall provide to the other, no later than seven (7) business days before the date
of the arbitration, the identity of all persons that may testify at the arbitration and a copy of all documents that may be introduced
at the arbitration or considered or used by a party’s witnesses or experts. The Arbitrator’s decision and award shall
be made and delivered within six (6) months of the selection of the Arbitrator. The Arbitrator’s decision shall set forth
a reasoned basis for any award of damages or finding of liability. The Arbitrator shall not have power to award damages in excess
of actual compensatory damages and shall not multiply actual damages or award punitive damages or any other damages that are specifically
excluded under this Agreement, and each party hereby irrevocably waives any claim to such damages in connection with any such arbitration.

 

(c) The parties
covenant and agree that they will participate in the arbitration in good faith and that they will (i) bear their own attorneys’
fees, costs and expenses in connection with the arbitration, and (ii) share equally in the fees and expenses charged by the
Arbitrator. Any party unsuccessfully refusing to comply with an order of the Arbitrator shall be liable for costs and expenses,
including reasonable attorneys’ fees, incurred by the other party in enforcing the award. In the case of temporary or preliminary
injunctive relief any party may proceed in court prior to, during or after arbitration for the purpose of avoiding immediate and
irreparable harm or to enforce its rights under any non-disclosure, confidentiality or non-competition covenants; provided, that
the right to equitable relief by a court is not intended to derogate from this arbitration procedure.

 

    	- 11 -

    	 

    

 

14.5. Assignment; Successors and Assigns, etc.
Neither the Company nor the Executive may make any assignment of this Agreement or any interest herein, by operation of law or
otherwise, without the prior written consent of the other party and without such consent any attempted transfer or assignment shall
be null and of no effect; provided, however, that the Company may assign its rights under this Agreement without the consent
of the Executive in the event either Company shall hereafter effect a reorganization, consolidate with or merge into any other
Person, or transfer all or substantially all of its properties or assets to any other Person. This Agreement shall inure to the
benefit of and be binding upon the Company and the Executive, and their respective successors, executors, administrators, heirs
and permitted assigns. In the event of the Executive’s death prior to the completion by the Company of all payments due his
under this Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the
Company prior to his death (or to his estate, if he fails to make such designation).

 

14.6. Enforceability.
If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court of competent
jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than
those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of
this Agreement shall be valid and enforceable to the fullest extent permitted by law.

 

14.7. Waiver.
No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any
party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this
Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

 

14.8. Notices.
Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered
in person or sent by registered or certified mail, postage prepaid, to the Executive at the last address the Executive has filed
in writing with the Company or, in the case of the Company, at its main office, attention of the board of directors.

 

14.9. Amendment.
This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative
of the Company.

 

14.10. Counterparts; Facsimile Signatures.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument, and in pleading or proving any provision of this Agreement it shall not be necessary
to produce more than one such counterpart. A signature sent by telecopy or facsimile transmission shall be as valid and binding
upon a Party as an original signature of such Party.

 

    	- 12 -

    	 

    

 

14.11. Governing Law.
This contract and shall be construed under and be governed in all respects by the laws of the State of Delaware without regard
to its conflict of laws principles.

 

* * * * *

 

IN WITNESS WHEREOF,
this Agreement has been executed by the Company, by its duly authorized officer, and by the Executive, as of the date first above
written.

 

	 	NOVELOS THERAPEUTICS, INC.	 
	 	 	 
	 	By:  /s/ Stephen Hill
	 	Name: Stephen Hill
	 	Title: Chairman of the Board of Directors
	 	 	 
	 	EXECUTIVE:	 
	 	 	 
	 	/s/ Simon Pedder	L/S
	 	Simon Pedder	 

 

    	- 13 -

    	 

    

 

Exhibit
A

 

Release

 

In consideration of
the undertakings by Novelos Therapeutics, Inc. (the “Company”) set forth in the Employment Agreement with the undersigned
(the “Employee”) dated October 4th, 2013, to which this Release is attached as an exhibit (the “Employment Agreement”)
and for other good and valuable consideration, the receipt of which is hereby acknowledged, Employee, on behalf of himself, his
successors, heirs, administrators, executors, assigns, agents, representatives, and all those in privity with him, releases and
forever discharges the Company, all of its present and former officers, directors, employees, servants, agents, representatives,
shareholders, successors, assigns, and beneficiaries, (collectively, the “Company Releasees”), of and from any and
all claims, charges, complaints, causes of action, demands, obligations, liabilities, damages, attorneys fees, expenses, and costs
of any kind which Employee now has or ever had arising out of his employment by the Company (“Released Claims”), including
but not limited to any causes of action or claims arising under or based on the National Labor Relations Act, as amended; the Civil
Rights Act of 1886, 42 U.S.C. § 1981; Section 2 of the Civil Rights Act of 1871, 42 U.S.C. § 1985(c); Title VII of the
Civil Rights Act of 1964, 42 U.S.C. § 2000a et seq., as amended by the Equal Employment Opportunity Act of 1972, 42 U.S.C.
§ 2000e et seq. and the Civil Rights Act of 1991, 42 U.S.C. § 1981a et seq.; the Equal Pay Act of 1963, 29 U.S.C. §206(d);
the Rehabilitation Act of 1973, as amended by the Americans With Disabilities Act and the 1991 Civil Rights Act, 29 U.S.C. §§
706(8), 791, 793, 794, 794a; the Americans with Disabilities Act of 1990, as amended by the Civil Rights Act of 1991, 42 U.S.C.
§ 12101 et seq.; the Age Discrimination in Employment Act (“ADEA”) of 1967, 29 U.S.C. § 621 et seq.; Executive
Order No. 11246, 3 C.F.R. 1964, reprinted as amended in 42 U.S.C. § 2000e; Massachusetts General Laws chapter 151B; Massachusetts
General Laws chapter 31; Massachusetts Generals Laws chapter 149; Massachusetts General Laws chapter 151; sections 111.310 through
111.395 of the Wisconsin Statutes; and any other state, federal or municipal equal employment opportunity law, statute, public
policy, order, ordinance, or regulation, and any other federal or state law, statute, order, public policy, or regulation affecting
or relating to the claims or rights of employees, and any and all Released Claims sounding in tort or contract or otherwise, which
Employee had, now has, or claimed to have, known or unknown, against the Company Releasees; provided, however, the foregoing
release shall not relate to any obligations of the Company arising under (i) the Employment Agreement relating to the payment
of severance and other post-termination payments, (ii) any equity award granted by the Company to the Employee, (iii) the
401(k) plan or similar retirement benefit plan of the Company and any agreements thereunder, or (iv) any statute, provision
of the Company’s certificate of incorporation or by-laws or insurance or other agreement providing indemnification rights
to Employee in connection with his services as an officer of the Company.

 

    	 

    	 

    

 

Employee acknowledges
and understands that the consideration Employee is being provided constitutes a full, fair and complete payment for the release
and waiver of all possible claims. Employee represents that Employee understands the various claims Employee could have asserted
under federal or state law, including but not limited to the Age Discrimination in Employment Act of 1967, as amended by the Older
Workers Benefits Protection Act, and other similar laws; that Employee has read this Release carefully and understands all of its
provisions; that Employee understands that Employee has the right to and is advised to consult an attorney concerning this Release
and in particular the waiver of rights Employee might have under these laws; that to the extent, if any, that Employee desired,
Employee availed himself of this right; that Employee has been provided at least twenty-one (21) days to consider whether to sign
this Release; that to the extent Employee has signed this Release before the expiration of such twenty-one (21) day period Employee
has done so knowingly and willingly; that Employee enters into this Release and waives any claims knowingly and willingly; and
that this Release shall become effective seven (7) days after it is signed. Employee may revoke this Release within seven (7) days
after it is signed and it shall not become effective or enforceable until this seven (7) day revocation period has expired.

 

	 	 
	 	Simon Pedder
	 	 
	 	Dated: _______________________, 20____

 

    	- 2 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]